Zynex Inc - ZYXI STOCK NEWS

Zynex, Inc. (Nasdaq: ZYXI), a leader in medical technology, announced an earnings webcast for Q4 and full-year 2020 on February 25, 2021, at 2:15 p.m. MT (4:15 p.m. ET). The webcast will cover their financial performance, although specific metrics were not disclosed in the PR. Stakeholders can register to attend the event online or via the provided dial-in numbers. Zynex specializes in non-invasive medical devices for pain management and rehabilitation.

Zynex, Inc. (NASDAQ: ZYXI) has promoted Anna Lucsok to Chief Operating Officer of Zynex Medical as of January 28, 2021, succeeding Joseph Papandrea. Lucsok, who previously served as Vice President of Reimbursement and Sales Operations, has extensive experience in healthcare operations and has significantly contributed to the company's sales and patient experience improvements. CEO Thomas Sandgaard expressed gratitude for Papandrea's contributions and optimism for Lucsok's leadership in driving growth and success in the company's operations.

Zynex, Inc. (NASDAQ: ZYXI) announced the filing for a provisional patent for a noninvasive sepsis monitor aimed at improving early detection of sepsis, a critical condition affecting over 1.7 million adults annually in the U.S. The monitor is designed to significantly enhance patient monitoring by providing advanced warnings of deteriorating health conditions due to sepsis. This innovation is expected to save lives and complement Zynex's existing CM-1500 Blood Volume Monitor, enhancing their product portfolio in medical technology.

Zynex, Inc. (NASDAQ: ZYXI) reported a remarkable 117% year-over-year growth in orders for Q4 2020, concluding the year with a 96% increase in orders despite the challenges posed by COVID-19. The company anticipates Q4 revenue between $25.5 million and $26.5 million, with an Adjusted EBITDA estimate of $3.1 million to $4.1 million. Zynex's full-year revenue is projected to be $80 million to $81 million, up 76% to 78% from last year. The company also increased its sales force to over 500 reps, aiming for approximately 600 by year-end 2021.

Zynex, Inc (NASDAQ: ZYXI) announced the acquisition of a second U.S. Utility patent for its Blood Volume Monitor Device, enhancing protection for its non-invasive technology. Inventor Thomas Sandgaard has assigned the patent to Zynex Monitoring Solutions. This innovation aims to address the critical need for managing patient blood volume in surgical contexts, particularly regarding internal bleeding in recovery and intensive care units. The FDA-cleared CM-1500 device is currently in full production.

Zynex, Inc. (NASDAQ: ZYXI) has been recognized as the 13th fastest-growing medical device company in North America by Deloitte's 2020 Technology Fast 500, with a remarkable revenue growth of 242% from 2016 to 2019. In 2019, Zynex reported revenues of $45.5 million and projects 2020 revenues between $80.0 million and $81.0 million. This accolade highlights Zynex's commitment to innovation in non-invasive medical devices, including pain management and stroke rehabilitation products.

Zynex, Inc. (NASDAQ: ZYXI) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference set for November 23 to December 3. Registered attendees can access presentations via the conference site, while 1X1 meetings are scheduled from December 1-3 and can be requested through Piper Sandler. Founded in 1996, Zynex specializes in non-invasive medical devices for pain management, stroke rehabilitation, and cardiac monitoring. For more details, visit Zynex.com.

Zynex reported third-quarter 2020 results with revenue reaching $20.0 million, a 69% year-over-year increase. The company achieved a net income of $1.3 million with diluted EPS at $0.04. Orders surged 96% compared to the same quarter in 2019. Adjusted EBITDA was $2.4 million, with working capital increasing to $50.3 million. For the full year, Zynex estimates revenue between $80 million and $81 million, reflecting an increase of 76% to 78% over 2019. The company remains optimistic despite COVID-19 challenges, emphasizing growth strategies and sales force expansion.

Zynex, Inc. (NASDAQ: ZYXI) announced the appointment of Neil Friery as President and COO of its Monitoring Solutions Division. This division focuses on non-invasive medical devices, including the CM-1500 Blood Volume Monitor, which received FDA clearance earlier this year. Founder and CEO Thomas Sandgaard expressed confidence in Friery's leadership, anticipating advancements in early detection technology for internal bleeding. Friery brings experience from Zimmer Biomet, where he significantly increased revenue in the Surgical Division.